Overview

Extended Management and Measurement of Autism

Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This open-label research study will continue to monitor the safety of fluoxetine in children after their completion of a previous double-blind placebo controlled clinical study, with fluoxetine. The study will also look at the effect of fluoxetine on IQ (Intelligence Quotient) over an 18 month period.
Phase:
Phase 3
Details
Lead Sponsor:
Neuropharm
Collaborator:
Autism Speaks
Treatments:
Fluoxetine